…
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Pharmaceuticals Inc. and changed its name to Algernon Health Inc. in October 2025. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Algernon Pharmaceuticals Inc is a clinical-stage pharmaceutical company developing small-molecule therapeutics. Long-term growth drivers may include progress in clinical programs, regulatory approvals, and partnering or licensing that could advance and commercialize pipeline assets. Investors may find the company attractive for upside tied to clinical milestones and potential pipeline expansion.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
| Income before tax | -1.72M | -0.50M | -6.78M | -6.05M | -7.73M |
| Net income | -1.72M | -0.50M | -6.78M | -6.05M | -7.73M |
| Selling general administrative | 1.64M | 1.76M | 4.15M | 3.73M | 3.25M |
| Reconciled depreciation | 0.05M | 0.03M | 0.05M | 0.03M | - |
| Ebit | - | - | - | -5.74M | -7.88M |
| Ebitda | - | - | - | -6.02M | -8.05M |
| Operating income | -1.72M | -2.41M | -5.24M | -6.06M | -8.05M |
| Interest expense | - | - | - | - | 0.00M |
| Interest income | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Net interest income | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.72M | 2.41M | 5.24M | 6.06M | 8.05M |
| Total other income expense net | - | 1.91M | -1.54M | - | 0.31M |
| Net income from continuing ops | -1.72M | -0.50M | -6.78M | -6.05M | -7.73M |
| Net income applicable to common shares | - | - | - | -6.05M | -7.73M |
| Breakdown | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
| Total assets | 4.88M | 3.94M | 4.19M | 8.14M | 10.14M |
| Intangible assets | 4.29M | 3.18M | 3.80M | 5.26M | 5.17M |
| Total liab | 2.18M | 1.78M | 2.72M | 2.52M | 1.02M |
| Total stockholder equity | 2.70M | 2.17M | 1.47M | 5.62M | 9.12M |
| Common stock | - | - | - | 27.12M | 25.85M |
| Capital stock | 30.17M | 29.56M | 28.15M | 27.12M | 25.85M |
| Retained earnings | -30.56M | -30.76M | -30.79M | -25.19M | -23.55M |
| Other assets | - | - | - | 0.06M | 0.06M |
| Cash | 0.18M | 0.60M | 0.13M | 1.41M | 2.41M |
| Total current liabilities | 2.18M | 1.78M | 2.72M | 2.52M | 1.02M |
| Other stockholder equity | - | - | - | 3.70M | 6.81M |
| Total current assets | 0.55M | 0.74M | 0.34M | 2.83M | 4.91M |
| Net tangible assets | - | - | - | 0.37M | 3.94M |
| Net receivables | - | - | - | 0.67M | 2.29M |
| Accounts payable | - | - | - | 2.24M | 1.02M |
| Non currrent assets other | 0.03M | 0.03M | 0.06M | 0.06M | 0.06M |
| Non current assets total | 4.32M | 3.21M | 3.85M | 5.31M | 5.23M |
| Breakdown | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
| Investments | - | 2.28M | -0.06M | -0.14M | -0.12M |
| Change to liabilities | - | - | - | 1.52M | 0.37M |
| Total cashflows from investing activities | - | - | - | -0.14M | -0.12M |
| Total cash from financing activities | 0.59M | 0.90M | 1.33M | 2.06M | 4.25M |
| Change to operating activities | - | - | - | -0.55M | 0.18M |
| Net income | -1.72M | -0.50M | -6.78M | -6.05M | -7.73M |
| Change in cash | -0.42M | 0.47M | -1.28M | -1.00M | -3.71M |
| Begin period cash flow | 0.60M | 0.13M | 1.41M | 2.41M | 6.12M |
| End period cash flow | 0.18M | 0.60M | 0.13M | 1.41M | 2.41M |
| Total cash from operating activities | -1.16M | -2.71M | -2.55M | -2.91M | -7.82M |
| Issuance of capital stock | 0.59M | 0.89M | 1.23M | 2.06M | 2.69M |
| Depreciation | 0.05M | 0.03M | 0.05M | 0.03M | 0.03M |
| Change to account receivables | -0.00M | 0.08M | 0.57M | 1.61M | -1.15M |
| Other cashflows from financing activities | - | - | - | 0.79M | 1.18M |
| Change to netincome | - | - | - | 0.52M | 0.51M |
| Capital expenditures | 0.02M | 0.08M | 0.06M | 0.14M | 0.12M |
| Change in working capital | 0.26M | -0.62M | 1.27M | 2.58M | -0.60M |
| Stock based compensation | 0.20M | 0.29M | 1.26M | 0.53M | 0.83M |
| Other non cash items | - | -0.25M | 0.04M | - | -0.31M |
| Free cash flow | -1.18M | -2.79M | -2.61M | -3.06M | -7.95M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| AGNPF Algernon Pharmaceuticals Inc |
- -% |
0.26 | - | - | - | 1.81 | -0.61 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Pharmaceuticals Inc. and changed its name to Algernon Health Inc. in October 2025. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher J. Moreau | CEO & Director | 1965 |
| Dr. Christopher Bryan Ph.D. | VP of Research & Operations | 1983 |
| Mr. James F. Kinley C.A., CPA | Chief Financial Officer | 1978 |
| Dr. Christopher Bryan Ph.D. | Vice President of Research & Operations | 1983 |
| Mr. James F. Kinley C.A., CPA | CFO & Corporate Secretary | 1978 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.